ClinicalTrials.gg
RecruitingNCT07488780Updated Sep 29, 2026

Language Network Prehab Via fMRI Neurofeedback

An interventional study of fMRI in Glioma and Glioma Surgery, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Yale University · Not applicable, Interventional, and Device feasibility

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Sep 29, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 851 studies in Glioma with a site in United States — 142 open to participants now, 229 under way, 6 of them phase 3. Glioma · United States.

Planned enrollment
677th of 737
4 · median 30
Started
2026
with 37 others
No phase
86 of 851
24 open now
Primary completion
2026-12
later than 58 of 228 live
Registered
829th of 851
by date

Among the 851 studies in Glioma with a site in United States, this one is the 677th largest by planned enrollment of the 737 interventional ones that give a count, is one of 38 that started in 2026, is one of 86 with no phase, reaches primary completion later than 58 of the 228 other live ones, and was the 829th registered.

Glioma

1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.

Browse Glioma studies →

Open to participants now

142 of the 851 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:

136 more — sign in →

All 142 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 851 studies in Glioma with a site in United States, or all of them as a file.
02

Study summary

This is an interventional neuroimaging study that will examine whether fMRI neurofeedback can shift language network activity away from regions affected by glioma prior to surgery.

Read the detailed description

The primary objective of this study is to establish the feasibility and acceptability of implementing a brief, device-based fMRI neurofeedback (NF) intervention during the standard presurgical window in patients with WHO grade II-III gliomas involving eloquent language cortex.

The secondary objectives of this study are to obtain preliminary mechanistic and behavioral data regarding the effects of fMRI NF-based prehabilitation on language network organization and language performance. These secondary objectives are exploratory and intended to inform the design of a future randomized clinical trial.

The intervention will be conducted during the standard preoperative window and will not alter or delay clinical care. All participants will receive the same neurofeedback intervention as the primary goal of this study is to establish feasibility and generate pilot data. The study involves repeated within-subject assessments, including baseline and post-intervention neuropsychological testing and task-based fMRI measures, allowing each participant to serve as their own reference point for exploratory analyses.

03

Conditions studied

  • Glioma
  • Glioma Surgery

Browse trials for

Keywords

  • fMRI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Diagnosis of WHO grade II-III glioma involving eloquent language cortex
  • Scheduled for surgical resection
  • MRI-compatible
  • Ability to perform the simple language tasks required for fMRI and neurofeedback
  • Residence within 2 hours of Yale MRRC and ability and willingness to make multiple visits for study participation

Exclusion criteria

Exclusion Criteria:

  • Severe baseline aphasia precluding task performance
  • to MRI
  • Significant cognitive/psychiatric comorbidity limiting compliance
  • Concurrent enrollment in other interventional trials
  • Claustrophobia of a degree that they cannot comfortably be scanned
  • Inability or unwillingness to understand or follow the instructions
  • Pregnancy or possible pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (estimated)

Study arms

  • Experimental
    fMRI neurofeedback (NF) and Glioma

    All participants will receive an fMRI NF intervention delivered as a presurgical prehabilitation strategy involving eloquent language cortex. The intervention will be conducted during the standard preoperative window and will not alter or delay clinical care. The study involves repeated within-subject assessments, including baseline and post-intervention neuropsychological testing and task-based fMRI measures.

    Device: fMRI

Interventions

  • DevicefMRI

    Real-time functional magnetic resonance imaging (fMRI) neurofeedback (NF)

06

What researchers measure

Primary outcomes

  1. Number of participants enrolled to assess feasibility

    Number of participants enrolled out of all screened

    Time frame: up to 6 months

  2. Number of participants completing all study visits to assess feasibility

    Number of participants completing all study visits within the standard presurgical window

    Time frame: From initial neurosurgical evaluation to scheduled tumor resection, 7-10 days

  3. Number of device-related adverse events to assess safety

    Number of device-related adverse events

    Time frame: From initial neurosurgical evaluation to scheduled tumor resection, 7-10 days

  4. Mean score Patient Experience Questionnaire (PEQ) to assess acceptability

    Participant-reported acceptability and perceived burden as measured by the Patient Experience Questionnaire (PEQ). Total score range 1-5 with higher scores indicating better experiences.

    Time frame: Post surgery at 10 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

Of 131 non-industry interventional studies with no phase under Glioma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 114. This study's planned 4 months is below that.

Counting every sponsor, half of 142 studies reached it within 58 months; a quarter within 34 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Mar 23, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 29, 2026
Sites
Yale School of Medicine is now Recruiting
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Not yet recruiting→Recruiting
    Yale School of Medicine is now Recruiting
    + 3 other changes: verification date, date precision and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07488780
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Aug 1, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 29, 2026

Study contacts

Luca Pasquini, MD, PhD
Contact
luca.pasquini@yale.edu
203-688-2433
Luca Pasquini, MD, PhD
principal investigator · Yale School of Medicin
Michelle Hampson, PhD
principal investigator · Yale University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion